EUVIMEDObjevte EUVIMED
Open access · CC BY-NC 4.0

Mass spectrometry redefines optimal testosterone thresholds in prostate cancer patients undergoing androgen deprivation therapy

Jérémie Beck, Mélanie Rouleau, Francis Lemire, Bertrand Neveu, Michel Déry, Benoît Thériault, Gabriel Dubois, Dominique Guérette, Frédéric Pouliot iD

The Prostate · 2023

DOI: 10.1002/pros.24501 ↗

At a glance

Journal article in The Prostate, 2023. Written by Jérémie Beck and 8 co-authors. Institution: Division of Urology, Department of Surgery and Cancer Research Center, Faculty of Medicine, Centre Hospitalier Universitaire (CHU) de Québec-Universi…. Major MEDLINE topics: Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant. Cited 2 times so far (Crossref); 26 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Sanofi Genzyme.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Androgen deprivation therapy (ADT) is the standard of care for prostate cancer treatment. Studies suggest that patients with testosterone levels below 0.7 nM have a longer time to castration resistance. Using the most accurate testosterone measurement method, namely mass spectrometry (MS), we sought to determine if a lower testosterone level under ADT could be associated with longer time to castration resistance.

Methods

This retrospective study included 138 prostate cancer patients undergoing noncurative continuous ADT for which we had access to testosterone measurements assessed by MS. For 108 samples, paired immunoassays (IA) testosterone measurement was available. Primary outcome was time to castration‐resistant prostate cancer (CRPC). The Contal and O'Quigley method was used to determine the optimal testosterone castration cut‐off point considering the outcome and time‐to‐event variables. Relationship between testosterone levels assessed either by IA or MS and time to CRPC was evaluated using Cox regression.

Results

Mean testosterone level was 0.370 nM by IA and 0.275 nM as assessed by MS. The optimal testosterone cut‐off point identified to predict time to CRPC was of 0.705 nM for IA and of 0.270 nM for MS. While no significant difference for time to CRPC was found between patients showing IA testosterone level ≥0.705 nM versus

Subjects

MeSH terms (MEDLINE)

Prostatic NeoplasmsProstatic Neoplasms, Castration-ResistantMaleHumansTestosteroneAndrogen AntagonistsAndrogensRetrospective StudiesOrchiectomy

Author keywords

androgen deprivation therapycastration-resistant prostate cancerimmunoassaymass spectrometryprostate cancertestosterone

Substances

TestosteroneAndrogen AntagonistsAndrogens

Authors and institutions

  • Division of Urology, Department of Surgery and Cancer Research Center, Faculty of Medicine, Centre Hospitalier Universitaire (CHU) de Québec-Université Laval, Québec, Québec, Canada.
  • Biochemistry Service, Medical Laboratory Department, CHU de Québec-Université Laval, Québec, Québec, Canada.

ORCID profiles: Frédéric Pouliot

Funding

  • Sanofi Genzyme

Cite

APA

Beck, J., Rouleau, M., Lemire, F., Neveu, B., Déry, M., Thériault, B., Dubois, G., Guérette, D., & Pouliot, F. (2023). Mass spectrometry redefines optimal testosterone thresholds in prostate cancer patients undergoing androgen deprivation therapy. The Prostate. https://doi.org/10.1002/pros.24501

Vancouver

Beck J, Rouleau M, Lemire F, Neveu B, Déry M, Thériault B, et al. Mass spectrometry redefines optimal testosterone thresholds in prostate cancer patients undergoing androgen deprivation therapy. The Prostate. 2023. doi:10.1002/pros.24501

BibTeX
@article{Beck2023,
  author = {Beck, Jérémie and Rouleau, Mélanie and Lemire, Francis and Neveu, Bertrand and Déry, Michel and Thériault, Benoît and Dubois, Gabriel and Guérette, Dominique and Pouliot, Frédéric},
  title = {Mass spectrometry redefines optimal testosterone thresholds in prostate cancer patients undergoing androgen deprivation therapy},
  journal = {The Prostate},
  year = {2023},
  doi = {10.1002/pros.24501}
}
Start for free →